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hyper-reactivity and polyclonal production of immuno-
globulins, and as a consequence, autoantibodies against pSS 
affected exocrine glands, especially lacrimal glands and 
salivary glands, but also other external glands such as the 
pancreas, mucous glands of the gastrointestinal and respira-
tory tract or bile secretion. In some patients, abnormal H+ 
secretion in the distal tubules has also been observed and 
caused distal renal tubular acidosis (type 1 RTA). In connec-
tion with the clinical symptoms which will result from the 
degree of attachment of these glands and epithelial injury, 
the pSS often uses the term “autoimmune epithelitis” or 
“autoimmune exocrinopathy” for better imaging of primary 
initiation sites of inflammation and autoimmunization.
A brief history
First lacrimal and salivary glands enlargement was 
described in a lecture of a Polish surgeon Jan Mikulicz–
Radecki in 1888. In 1925, French dermatologists Henri 
Gougerot described a few cases of atrophy of the salivary 
glands with dryness of eyes, mouth and vagina. Later in 
1933, Swedish ophthalmologists Henrik Sjögren in his 
doctoral thesis described keratoconjunctivitis sicca, and his 
description became a basis for pSS picture.
Epidemiology
It is estimated that primary Sjögren’s syndrome occurs 
from 0.1 to 3.0 % in general population. The disease is 
more common for women (female/male ratio 9:1), mainly 
between the ages of 40–60, with the disease most fre-
quently occurring around 50 years of age.
Pathogenesis of pSS is not clear, nowadays several fac-
tors responsible for the development of the disease, such as 
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genetic factors—genes implicated in B cell or B-cell acti-
vation factor (BAFF) known also as B-Lymphocyte Stimu-
lator (BLyS), lymfotoxin α and β and TNF (tumor necrosis 
factor) are taken into account. Furthermore, it is presumed 
that genetic predisposition to increase in type I interferon 
(IFN) may explain the IFN signature and activation of type 
I IFN signaling in salivary gland and peripheral blood in 
pSS patients. The HLA-B8, of HLA-Dw3 and HLA-DR3 
and DRw52 have also been reported in pSS patients [1, 2]. 
Another factor responsible for the development of pSS is 
an infection caused mainly by Epstain–Barr virus (EBV), 
human T-cell lymphotrophic virus type-1 (HTLV-1), Cyto-
megalovirus (CMV) and Hepatitis C virus (HCV). Also 
neurohormonal disturbances with sex hormones and its 
receptors dependent on hypothalamic–pituitary–adrenal 
axis (HPA or HTPA axis) interfere with the ratio of estro-
gens to androgens and affect steroid-dependent cells like 
epithelial cells and other cells involved in the immune 
response [3]. In pSS patients, lower basal secretion of 
ACTH and cortisol has been found. In addition, hypotha-
lamic–pituitary–gonadal (HPG) axis by estrogen deficiency 
can be responsible for a local autoimmune exocrinopathy 
[4]. It is assumed that the infection as the trigger (most 
commonly viral) and other environmental factors caused 
the disorganisation of epithelial cells. First, due to innate 
immune response, virus infection is recognized by pattern 
recognition receptor (PRR) and activates toll-like recep-
tors (TLR) pathway (e.g., TLR 3, 7, 9). After the activa-
tion, the innate immune response TLR, cell apoptosis and 
SS-A RNA complexes stimulate plasmocytic dendritic cells 
(pDCs) which produce high level of interferons (IFNs) 
and IFNs as strong stimulators of BAFF production by 
epithelial cells, monocytes and neutrophils dendritic cells 
leading to proliferation and differentiation of B cells and 
production of autoantibodies. It is suggested that glandu-
lar cell apoptosis triggered by viral infection (EBV, HCV 
and HIV) leads to progressive damage of glands and their 
dysfunction with reduced secretion and the appearance of 
classic clinical symptoms. Damaged epithelial cells release 
autoantigens, especially Ro/SSA and La/SSB, which cre-
ate autoimmunity and autoantibodies secretions. The pres-
ence of Ro/SS-A antibodies (anti-Ro52 and anti-Ro60) is 
correlated with longer duration of pSS, bigger destruction 
of the glands and extraglandular manifestation. Plasmocy-
toid dendritic cells (pDCs) migrate into the site of damage. 
pDC is the source of type I INF and initiates the activa-
tion of B cell by B-cell activation factor (BAFF) pathway. 
However, epithelium is infiltrated mainly by CD 4+ lim-
phocytes T subtype and immune response is balanced 
toward Th1 response and also Th17—with interleukin 
17(IL-17) as a main cytokine. Th1 cells produce interferon 
gamma (IFN γ) which induces plasminogen activator sys-
tem and together with IL-17 promotes local inflammation. 
In advanced stages of inflammation, B cells have been 
detected in salivary glands or other places in exocrine sys-
tem. Recent study suggests that IL-7 from IL-7+ periph-
eral blood T cells may contribute to the stimulation of Th1 
and Th17 cytokines [5]. It has been recently discovered that 
newly identified cytokine IL-34 promotes overexpression 
of CD 14+ monocytes in salivary glands. IL-34 and CSF-1 
(colony stimulating factor-1) stimulate survival, prolifera-
tion and differentiation of monocytes, macrophages, den-
dritic cells, Langerhans cells and osteoclasts—cells which 
have the ability to phagocytose [6]. Studies have shown 
that also IL-21, cytokine produced by activated CD 4+ T 
limphocytes and NKT cells play a role in pathogenesis of 
pSS and correlate with lymphocytes infiltration of salivary 
gland as well as the presence of autoantibodies and level of 
gammaglobulins. This cytokine stimulates TH1 and Th17 
differentiation and synergistically with BAFF stimulates 
B-cells differentiation [7]. As in many autoimmune dis-
eases, the increased level of IL–6 has been found in pSS. 
IL-6 is one more cytokine which enhances lymphocytes 
B growth and maturation. As well as IL-6, it has a strong 
influence on persistence of inflammation [8]. The produc-
tion of IL-6 by monocytes in pSS is strongly stimulated 
by INF γ. The increased activity of IL-6 may influence the 
clinical symptoms, and increased IL-6 has been reported in 
saliva, serum and tears [8] The break of T cells tolerance by 
viral infection leads to the activation of self-reactive T cells 
which by BAFF stimulate activation and maturation of B 
cells. Extended B-cell activation by BAFF generates self-
reactive memory B cells which serve as an antigen-present-
ing cells to T cells. The crucial role of B limphocytes in 
pSS seems obvious—all pathways lead to powerful stimu-
lation of B-cells maturation and to their hyper-reactivity, 
polyclonal production of gammaglobulins and the emer-
gence of autoantibodies, which are B cell related markers 
for pSS. At first stage of inflammation, macrophages and 
T cells are infiltrating salivary glands, but over the time 
in the glands accumulate memory B cells and their level 
decreases in peripheral blood, while the level of naïve and 
transitional B cells increases. Interesting work presented by 
Bohnhorst et al. [10] showed disturbances in subset of B 
cells in pSS and differences in proportions between naïve 
B cells and memory cells in peripheral blood [9, 11]. Bal-
dini and collegues [12] assessed a prevalence of vitamin 
D deficiency in early stage of the disease, considered the 
impact of hypovitaminosis D in clinical symptoms and dis-
ease activity, expressed by the symptoms of dryness and 
concluded that hypovitaminosis D is relatively frequent in 
patients with pSS. The investigators speculated that vitamin 
D may have the effect on Th1 cells and regulatory limpho-
cytes, dendritic cells and CD 8+ T cells and plays a role 
in pSS pathogenesis. But the fact that vitamin D deficiency 
may be an independent and associated with reduced supply 
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and reduced synthesis of this vitamin in relation to the liv-
ing conditions and nutrition cannot be exclude. In another 
work, Agmon Levin et al. [13] showed the relationship 
between reduction of level of vitamin D and the occurrence 
of peripheral neuropathy and also of nonHodgkin lym-
phoma. The pathogenesis of Sjögren’s syndrome schematic 
is shown in Fig. 1
Autoantigens and autoantibodies
The most commonly present autoantibodies in pSS are 
antibodies against cellular ribonucleoprotein antigens Ro/
anti-SS-A and LA/SS-B. These autoantibodies are not spe-
cific for pSS, only but their presence is associated with 
severe glandular manifestations, longer duration of the dis-
ease, presence of splenomegaly, lymphadenopathy, vascu-
litis and high infiltration of salivary glands. Ro52 antibod-
ies were reported in about 80 % of pSS patients. In pSS, 
rheumatoid factor (RF) correlating with early stage of 
disease and onset of the disease at a younger age is often 
appearing. RF is present in about 74 % of patients with pSS 
and may also be associated with extraglandular symptoms 
such as arthritis. In 17 % of pSS anti-centromere antibod-
ies (ACA), which are more specific for limited systemic 
sclerosis, were found. Their presence may signal an overlap 
syndrome [14].
The prevalence of antinuclear antibodies (ANAs) in pSS 
reaches 80 %, together with RF, in the case of the absence 
of anti-Ro/La along with histopathological confirmation or 
confirmation of ocular lesions allows make pSS diagnosis 
according to the ACR criteria. ANAs are also a predictor 
of internal organ involvement and the development of lym-
phoproliferative disorders. In pSS, M3 muscarinic acetylo-
choline receptor (M3R) is expressed in exocrine glands and 
its activation is important in the process of exocrine secre-
tion. Sumida and colleagues found that M3R reactive T 
cells (Th1 and Th17) occur in 40 % in peripheral blood of 
patients with pSS and autoantibodies against M3R may play 
an important role in the development of autoimmune sialad-
enitis [15, 16]. In pSS patients, anti-mitochondrial antibodies 
(AMA), which are characteristic for primary biliary cirrhosis 
(PBC), can occur. In these patients, changes in the liver are 
more likely to appear, with periductal lymphocytic infiltrat-
ing analogously the changes in salivary glands. Abnormal 
liver function test (increased AST and/or ALT, AP and/or 
bilirubin) is common in pSS as extraglandular manifestation 
of the disease as well as overlapping with another disease as 
PBC or autoimmune hepatitis [16, 17]. Anti-smooth mus-
cle antibodies (ASMA) are characteristic for autoimmune 
type 1 hepatitis which can also be found in pSS patients 
[18]. Also autoantibodies against carbonic anhydrase (anti-
CAII) are present in pSS and are associated with distal renal 
tubular acidosis [19]. The anti-cyclic citrulinated peptide 
antibodies (anti-CCP), which are highly specific for RA, 
are not frequent in patient with pSS. The presence of anti-
CCP antibodies may be associated with joint erosions and 
synovitis. Also it cannot be excluded that the patient who 
has anti-CCP antibodies and rheumatoid factor (RF-IgM) 
will develop symptoms of RA in the future [20]. In addi-
tion, autoantibodies with direct cytoskeletal proteins-α and 
Fig. 1  Sjögren’s syndrome outline of pathogenesis. TLRs toll-like receptors, INF interferon, BAFF B-cell activating factor, IL interleukin, DC 
dendritic cell, B B cell, Th T cell, TNF tumor necrosis factor, PC plasmocytic cell
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β fodrin and proteasomes have been found in patients with 
pSS. The current studies showed additional autoantibodies in 
pSS to salivary gland as follows: protein 1 (SP-1), carbonic 
anhydrase 6 (CA6) and parotid secretory protein (PSP) [21]. 
Organ-specific antibodies, such as anti-thyroglobulin (anti-
TG) and anti-thyroid peroxidase antibodies (anti-TPO), most 
characteristic for autoimmune thyroiditis, were also found. 
D’Arbonneau and colleagues reported that thyroid disease 
was more frequent in pSS patients in up to 30 % of patients 
compared with 4 % of the control group [22]. However, the 
presence of anti-TPO and TG antibodies in pSS may also not 
be related to the coexistence of Hashimoto’s disease [23].
Clinical picture of the disease
The clinical picture of pSS includes symptoms of dryness 
and extraglandular manifestations with organs involve-
ment. Patients’ complaints of the dryness are the basis 
for suspicion. The dryness concerns first of all the mouth, 
eyes and vagina—the latter especially in postmenopausal 
women. The clinical signs are presented in Table 1. Among 
laboratory findings, cytopenias (leucopenia, anemia and 
low platelet count) are the most typical. Elevated erythro-
cyte sedimentation rate (ESR), hypergammaglobulinemia, 
ANAs, RF, anti-Ro/SS-A, anti-B/SSB, decreased level of 
Table 1  Clinical features of 
primary Sjögren’s syndrome Dryness
Xerostomia (dry mouth) Diminished secretion of saliva
Troubles with swallowing
Dental caries
Fungal and bacterial infections









Arthritis—nonerosive, also rheumatoid arthritis—like myositis
Respiratory tract Cough—dryness of trachea or bronchitis
Intestinal like disease
Gastrointestinal system Dysphagia (dryness of pharynx and esophagus), gastrointestinal reflux
Chronic gastritis with atrophy
Liver involving (rather mild)
Symptoms of PBC and AIH (autoimmune hepatitis)
Celiac-like disease
Urinary tract Distal renal tubular acidosis (RTA type 1)
Nephrocalcinosis (in same cases due to RTA)
Nepritis/glomerulonephritis
Chronic renal insufficiency
Vessels and skin Reynaud’s phenomenon (scleroderma like patterns with ACA antibodies)
Vasculitis
Urticaria, palpable purpura, annular erythrema
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complement component C4 and cryoglobulins are more 
often laboratory abnormalities in patients with pSS.
Classification criteria for pSS and tools useful in the 
diagnosis
Classification criteria of pSS have evolved from 1960s till 
new proposed in 2012. Since 2002, clinicians used criteria 
established and revised by American–European Consen-
sus Group (AECG), which are based on six points: sub-
jective and objectives features of dry eyes and dry mouth, 
the patient’s need to fulfill at least three subjective or two 
objective features and the presence of Ro/SS-A or La/SS-
B antibodies or both, or inflammation in minor salivary 
glands with focus score (FS) equal or more than 1. FS 
is defined as 50 inflammatory cells in a 4-mm2 glandu-
lar section in material from minor salivary gland biopsy 
(SGB). Newly proposed ACR classification criteria for pSS 
assumed that in the cases with Ro/SS-A and La/SSB nega-
tive, but with symptoms suggestive for pSS and FS >1 in 
SGB the presence of ANAs titer above/equal to 1:320, and 
the presence of rheumatoid factor is sufficient to establish 
a diagnosis [24, 25]. This year Rasmussen et al. [26] com-
pared new ACR criteria and AECG criteria and showed no 
significant differences and assumed ACR criteria sensitiv-
ity to 87.5 (95 % CI 82.9–90.9), specificity 93.4 (95 % CI 
86.8–94.00, negative predictive value (NPV) 90.7, positive 
predictive value (PPV) 91. Among the 268 patients, who 
have met ACR criteria, 8.9 % did not fulfill AECG criteria, 
and among 279 patients, who fulfilled AECG criteria, 35 
were not evaluated using ACR criteria. The differences are 
due to the fact that not all patients had keratoconjunctivi-
tis sicca or positive serology and histopathological changes 
did not occur simultaneously. On the other hand, the 
patients that met only ACR criteria have been negative for 
Ro/La antibodies, but RF and ANAs positive. Comparative 
summary AECG criteria and ACR are shown in Table 2.
Diagnosis of pSS according to AECG criteria requires 
the assessment of salivary glands or salivary gland scin-
tigraphy or sialography which is a specific, but invasive 
method of imaging. Unstimulated salivary flow and sialom-
etry are other diagnostic tools to assess the function of 
Table 2  Comparison of AECG and ACR proposed 2012 criteria for pSS [24–26]
The revised AECG criteria 2002 ACR proposed criteria 2012
Subjective symptoms Subjective symptoms
1. Ocular symptoms
 Persistent dry eyes for more than 3 months?
 Recurrent sensation of sand or gravel in the eyes?
 Using tear substitutes more than three times a day?
Not included
2. Oral symptoms
 Feeling of dry mouth for more than 3 months?
 Recurrent or persistent swollen salivary gland?
 Frequent drinking to aid swallowing?
Objective symptoms/examinations Objectives symptoms
3. Schirmer’s test without anesthesia (<5 mm/5′
 Rose Bengal score >4 in van Bijsterveld’s scoring system
1. Positive serum autoantibodies to Ro/SS-A or La/SS-B or both or 
positive rheumatoid factor and ANA ≥ 1:320
4. Histopathology-focus score ≥ 1 2. Salivary gland biopsy-focus score ≥1
5. Slivary gland involvement—positive results in one of:
 Unstimulated salivary flow (<1.5 ml in 15 min
 Sialography showing the presence of sialectasis without destructions of 
major ducts
 Scintigraphy with reduced uptake and concentration and/or excretion 
of tracer
3. Keratoconjunctivitis sicca with ocular staining score in individuals 
who is not using eye drops for glaucoma, and has not corneal surgery 
or cosmetic lid surgery in the last 5 years
6. Autoantibodies to Ro/SS-A or La/SS-B or both
Exclusions Exclusions
Head and neck radiation Head and neck radiation
Hepatitis C infection Hepatitis C infection
AIDS (acquired immune-deficiency syndrome) Sarcoidosis
Pre-existing lymphoma Amyloidosis
Sarcoidosis AIDS (acquired immune-deficiency syndrome)
GVH (Graft versus Host) disease GVH disease
Use of anticholinergic drugs IgG4-related diseases
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salivary glands [27]. ACR criteria avoid such methods, lim-
iting the estimation of salivary glands for histopathological 
examination. However, for clinicians, especially in the case 
of lack of patient’s consent for salivary gland biopsy, it is 
important to have a simple, available and noninvasive diag-
nostic tool for the assessment of salivary glands. It appears 
that salivary gland ultrasonography (SGUS) meets these 
assumptions. SGUS is relatively cheap, available and can 
be use not only for making a diagnosis, but also for control-
ling a disease progression and conversion into lymphoma. 
In Theander and Thomas study, 105 patients with pSS and 
57 individuals in control group were evaluated by SGUS 
[28]. The authors used a simplified scoring system to evalu-
ate salivary glands, taking into account the parenchymal 
echogenicity and inhomogeneity. This scoring system has 
been proposed by Hocevar [29] from normal echogenicity 
to next steps of hypoechoics lesions. For pSS, the score of 
2 or 3 is characteristic. This method of scoring seems to 
be good for more advanced stages of the disease and can 
predict, together with laboratory findings, such as positive 
Ro/La antibodies, the presence of RF and ANAs in more 
severe disease and a higher risk of lymphoma development. 
Other researchers evaluate glands size, clearness of bor-
ders and vascularity, but it is currently believed that only 
parenchymal homogeneity is appropriate for the diagnosis 
of changes in pSS [30]. Other methods, such as MR sialog-
raphy and computed tomography (CT), may have limited 
availability and are undoubtedly more expensive. The basis 
of the diagnosis and a strong argument of inflammation and 
lymphocytes infiltration of salivary glands is histopatholog-
ical examination. Standardization of techniques of minor 
salivary glands biopsy makes it possible to reduce the risk 
of complications and even increase the value of this study. 
Varela-Centelles et al. [30] suggested the use of S forceps 
for better positioning of the lower lip than chalazion for-
ceps and to avoid postoperative complications [31]. In his-
topathological assessment in pSS focal infiltrates, CD 4+ T 
cells in early stage and more memory B cells in next stages 
are observed, further aggregation of limphocytes, organized 
lymphoid follicle, ectopic germinal center-like structure 
(GC) and in some cases lymphoma picture. The degree of 
organization of infiltration correlates with the severity of 
the disease, large activity of cytokines in situ and by the 
presence of autoantibodies [32].
Sjögren’s syndrome and IgG4‑related diseases
The cases of lacrimal and salivary glands being affected by 
the disease, that manifests itself with the symptoms of dry-
ness and is accompanied by autoimmune pancreatitis and 
renal disease (IgG4-related kidney disease), have for years 
been recognized as a subtype of pSS. Japanese clinicians 
and scientist first demonstrated that such patients show 
lymphoplasmocytic infiltrations with IgG4 plasma cells. 
Additionally, diffuse or local organ enlargement, fibrosis 
and/or hyperplastic lesions with symptoms of organ dam-
age have been observed in this group. The term “IgG4-
related diseases” was finally proposed with classification 
criteria for IgG4 RD established. IgG4 RD affects mainly 
elderly man (>60 years old) [33]. The serum level of IgG4 
is significantly (>135 mg/dl) increased, and a tissue biopsy 
reveals infiltrations of IgG4 plasma cells, with IgG4/IgG 
ratio exceeding 40 %. Patients’ plasma tests seronegative 
for the presence antinuclear antibodies, including SS-A and 
SS-B. Hypocomplementemia, high serum levels of poly-
clonal gammaglobulins with increased level of IgG4 and 
IgE gammaglobulins may also occur. The histopathologi-
cal assessment shows plasmocyte and lymphocyte infiltra-
tions and may reveal fibrosis. Establishing the diagnosis of 
IgG4 RD requires first of all the exclusion of malignancy, 
for which task histopathological examination is vital. Other 
diseases, chiefly pSS, but also Castelman’s disease, ANCA-
associated vasculitis, idiopathic retroperitoneal fibrosis, 
sarcoidosis should also be considered as an alternative 
diagnosis and excluded, using diagnostic criteria for each 
of the listed diseases. Differences between pSS and IgG4 
RD are presented in a Table 3.
HCV infection and primary Sjögren’s syndrome: a topic 
for discussion
Patients infected with HCV may have dryness and cryoglo-
bulinemia, but Ro/SS-A and La/SS-B antibodies are rarely 
present in the HCV infection. The discussion invokes the 
potential role of HCV infection in the pathogenesis of pSS. 
Various studies depict the presence of HCV in 14–19 % of 
patients with pSS. Ramos-Casals et al. [34] conducted a 
study of 137 patients diagnosed with pSS and co-infected 
with HCV. In 50 % of this group, cryoglobulins were pre-
sent, and only 23 % had antibodies to Ro/SS-A and/or 
La/SS-B, 65 % had ANA antibodies. The authors suggest 
that chronic HCV infection must be considered as a cri-
terion for exclusion pSS mainly by influencing the devel-
opment and course of pSS and also proposed the term 
secondary to HCV Sjögren’s syndrome. Also at work, 
Madalin´ski et al. [35] who examined 104 patients diag-
nosed with pSS searched for markers of infection HCV and 
in 19.2 %—HCV antibodies were found and 4.8 % patients 
had genetic material of the virus (HCV-RNA); researchers 
also suggested distinguish disease as different from pSS.
Risk of lymphoma and development of other cancers
Patients with pSS have a significantly higher risk of the 
development of EBV-associated lymphomas. EBV DNA 
that was found in saliva and B cells. This presence of 
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epithelial cells in salivary glands suggests active infection 
(reactivation of EBV). The development of lymphoma has 
been described in 4–7 % of patients with pSS [36, 37]. This 
applies particularly to the development of MALT (mucosa-
associated lymphoid tissue) lymphomas and also splenic 
marginal zone lymphomas (SMZL) as well as nodal mar-
ginal zone lymphoma (NMZL) [37]. For years, a risk fac-
tors associated with the development of lymphomas have 
been analyzed—taking into account both clinical symp-
toms and potential biomarkers associated with the devel-
opment of lymphoproliferation, which are presented in the 
Table 4 [38, 39].
*Fms-like tyrosine kinase ligand is a cytokine-stimulat-
ing growth of bone marrow and blood progenitor cells, and 
Flt 3 expression is described in lymphoma cells [40].
Treatment of pSS
Symptomatic treatment In the case of symptoms of dry 
eyes, artificial tears are used, topical drops with cyclosporin 
A and corticosteroids. In more severe cases, it is necessary 
to close the lacrimal ducts. Dry mouth treatment is lim-
ited to recommending drinking larger quantities of fluids, 
gentle acidification of fluids and the use of artificial saliva. 
Systemic administration of drugs to enhance salivating 
includes agonists muscarinic receptors: pilocarpine and 
cevimeline [41]. Sometimes N-acetylocysteine may be use-
ful. It is important to treat fungal infections of the oral cav-
ity. Vaginal dryness and dysperunia should be treated with 
lubricants, propionic acid gels, and sometimes, in the case 
of menopause, vaginal cream with estrogens.
Systemic treatment is based on antimalaric drugs such 
as hydroxychlorochine and especially in the case of arthri-
tis methotrexate, corticosteroids, cyclosporine A and aza-
thioprine. In severe cases, with life threat involving organs 
(renal involvement, neurological, pulmonary involvement 
and vasculitis) cyclophosphamide, infusions of immuno-
globulin, plasmapheresis is used. Patients with renal tubu-
lar acidosis should receive sodium and/or potassium.
Potential new therapies In view of the demonstrated key 
role of B cells—their hyperstimulation and overproduction 
of autoantibodies in pSS—B cells have become a logical 
target for therapy. Rituximab (RTX), chimeric antibody 
against anti-CD20, has proven effective in reducing both 
the destruction of the salivary glands, reducing inflamma-
tory infiltration in salivary glands, which not only shows 
the effect on the depletion of B cells, but also on T lym-
phocytes. Also after infusion of rituximab, significant 
Table 3  Differences between pSS and IgG4 RD
Primary Sjogren’s syndrome IgG4-related diseases
Age between 30 and 50 Age >60
Mainly women Mainly men
Salivary glands enlargement may occur Organ enlargement (local or diffuse)
Symptoms of dryness Symptoms of dryness may occur
Presence of ANA antibodies Absence of antinuclear antibodies
Presence of anti-SS-A, SS-B antibodies Absence of anti-SS-A SS-B antibodies
Polyclonal hypergammaglobulinemia Polyclonal hypergammaglobulinemia
Normal level of IgG4 Significantly increased level of IgG4
Mainly CD 4+ T lymphocyte infiltrations Mainly IgG4-positive plasmocytic infiltrations IgG4/IgG ratio >40 %
Treatment: symptomatic and systemic (antimalarics, methotrexate,  
corticosteroids, cyclosporine A, azathioprine, cyclophosphamide)
Treatment: steroids (no response to steroid treatment indicates incorrect 
diagnosis)
Table 4  Clinical manifestations and biomarkers associated with lymphoma development in pSS
Clinical manifestations Potential biomarkers
Vasculitis Cryoglobulins (mixt cryoglobulinemia)
Salivary gland enlargement Low C4 complement component
Salivary gland/parotid swelling Anti-Ro/SS-A antibodies
Lymphadenopathy Leukopenia
Splenomegaly Presence of RF expressing B cells
Peripheral neuropathy *Flt3-L (Fms-like tyrosine kinase3 ligand)
Long duration of pSS Higher levels of BAFF/BLyS
Histopathology: germinal-like structures in minor salivary glands biopsy
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decrease of rheumatoid factor Ig-M in serum was observed 
[42]. RTX treatment had also an influence on reduction of 
symptoms of dryness, fatigue and artralgias. Efficacy of 
B-cell depletion in pSS initiated further search for drugs-
affecting B cells and BAFF/BlyS as a main stimulator of B 
cells has become a new target of therapy. Belimumab is a 
monoclonal antibody which inhibits the biological activity 
of B-Lymphocyte stimulator (BLyS), currently accepted in 
SLE treatment. BELLIS open label phase II study showed 
benefits of belimumab in patients with pSS, but further 
studies are needed [43, 44]. Epratuzumab is the human-
ized anti-CD22 monoclonal antibody that causes moder-
ate B-cell depletion, therefore, can be another toll for pSS 
treatment. However, previous research showed clinical 
improvement with no influence on level of autoantibod-
ies [45, 46]. The future of pSS treatment may be an IFN-
related therapies and influence on IFN-related pathways. 
Mesenchymal stem cells (MSCs) transplantation, thanks to 
low immunogenicity and ability of multipotent stem cells 
to differentiate into various cells, seems to be promising 
method in pSS. The effectiveness of such treatment has 
been demonstrated in SLE and systemic sclerosis [47].
Conclusions
Particular challenge is to make the pSS diagnosis in the 
early stages of the disease. The presence of typical pSS 
serological markers such as anti-SS-A and anti-SS-B anti-
bodies at an early stage cannot be confirmed, which is taken 
into account in the newly proposed ACR classification cri-
teria. Discoveries of novel cellular subsets and cytokines 
involved in pSS pathogenesis may become a new target for 
future therapies. Both gene transfer and MSC transplanta-
tion can find wider application in the pSS treatment.
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